Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 7/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 4/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22439730 | 0.87 | PPARA (0.45) | S1PR2XDHPPARAPPARGSCN9A | |
| SCHEMBL28319259 | 0.87 | PPARA (0.47) | S1PR2PPARAPPARGSCN9APPARD | |
| SCHEMBL17870007 | 0.86 | POLB (0.57) | TSHRCASP1SMN1; SMN2POLBKMO | |
| SCHEMBL28521601 | 0.86 | TSHR (0.63) | TSHRCASP1SMN1; SMN2XDHPPARG | |
| SCHEMBL27666335 | 0.85 | TSHR (0.52) | TSHRCASP1SMN1; SMN2XDHPPARG | |
| SCHEMBL524088 | 0.84 | POLB (0.63) | XDHPOLBDHODH | |
| SCHEMBL21838875 | 0.83 | TSHR (0.50) | TSHRCASP1SMN1; SMN2XDHPOLB | |
| SCHEMBL21274783 | 0.83 | MAOB (0.51) | S1PR2XDHPPARASCN9APOLB | |
| SCHEMBL3139349 | 0.83 | HPGD (0.47) | S1PR2SMN1; SMN2PPARAPPARGSCN9A | |
| SCHEMBL3140116 | 0.81 | KDM4E (0.55) | S1PR2PPARAPPARGSCN9APPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004221-A1 | THIAZEPINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2119719-A1 | THIAZEPINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004221-A1 | THIAZEPINE DERIVATIVE | HSD11B1, HSD17B1, HSD3B1 | S1PR2 1805/4885TSHR 359/4885CASP1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.